An Investigation of the Prescription Patterns of Chinese Herbal Products for Chronic Glomerulonephritis Patients: A Hospital-Based Cross-Sectional Study
Table 5
eGFR (ml/min) analysis results divided into five groups with different stages (n=386).
eGFR
Group
number (N)
Before treatment (Mean ±SD)
After treatment within 6 months (Mean ±SD)
P
After treatment within 12 months (Mean ±SD)
P
Stage 1~2
71
97.85±65.18
102.5±76.48
0.24
102.19±59.64
0.28
Stage 3a
78
51.89±4.39
57.38±10.48
0.00
55.79±12.71
0.01
Stage 3b
81
37.67±4.37
41.77±9.87
0.00
40.01±10.87
0.04
Stage 4
72
21.8±4.35
24.34±8.03
0.00
21.23±8.79
0.49
Stage 5
84
9.12±3.55
12.82±14.78
0.02
11.53±19.09
0.24
※P value for the use of CHPs before treatment and after treatment within 3-6-9 months. The P value < 0.05, indicating significant differences.
